Lupin - Intellectual Property Management Group (IPMG) Research Services
Lupin`s IPMG is responsible for creating, securing, and leveraging a portfolio of high-value patents, products, and research pipeline projects. IPMG has also successfully managed patent challenges in courts and patent offices around the world.
In FY2020, the company was first-to-file with respect to generics versions of Juluca® Tablets, Entresto® Tablets, Rexulti® Tablets, Odefsey® Tablets, Descovy® Tablets, Vemlidy® Tablets, and Bridion® Intravenous Solution.
Cumulative ANDA and NDA filings with U.S. FDA now stand at 430 and 7 respectively, with approvals of 273 and 4 respectively, as of FY2020. Lupin has a total of 43 first-to-file ANDAs pending launch, which includes 14 exclusive first-to-file opportunities.
In FY2020, the company settled 8 pending U.S patent litigations and received a favourable U.K. court decision in its challenge to the Truvada® SPC.